Literature DB >> 17188480

In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium reniforme, Pelargonium sidoides and the related herbal drug preparation EPs 7630.

Herbert Kolodziej1, Albrecht F Kiderlen.   

Abstract

The importance of Pelargonium species, most notably Pelargonium reniforme and Pelargonium sidoides, in traditional medicine in the Southern African region is well documented. Nowadays, a modern aqueous-ethanolic formulation of the roots of P. sidoides (EPs) 7630) is successfully employed for the treatment of ear, nose and throat disorders as well as respiratory tract infections. To provide a scientific basis of its present utilization in phytomedicine, EPs 7630, extracts and isolated constituents of the titled Pelargoniums with emphasis on P. sidoides were evaluated for antibacterial activity and for their effects on nonspecific immune functions. The samples exhibited merely moderate direct antibacterial capabilities against a spectrum of Gram-positive and Gram-negative bacteria. Functional bioassays including an in vitro model for intracellular diseases, a fibroblast-lysis assay (tumour necrosis factor (TNF) activity), a fibroblast-virus protection assay (IFN activity) and a biochemical assay for nitric oxides revealed significant immunomodulatory properties. Gene expression experiments (iNOS, IFN-alpha, IFN-gamma, TNF-alpha, Interleukin (IL)-1, IL-10, IL12, IL-18) not only confirmed functional data, they also clearly showed differences in the response of infected macrophages when compared to that of noninfected cells. ELISA confirmed the protein production of TNF-alpha, IL-1alpha and IL-12, while FACS analyses reaffirmed the cytokines IL-1alpha and IL-12 at the singular cell level. The current data provide convincing support for the improvement of immune functions at various levels, hence, validating the medicinal uses of EPs 7630. Despite considerable efforts, the remedial effects cannot yet be related to a chemically defined principle.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17188480     DOI: 10.1016/j.phymed.2006.11.020

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  15 in total

1.  [Pelargonium sidoides in acute bronchitis - Health-related quality of life and patient-reported outcome in adults receiving EPs 7630 treatment].

Authors:  Heinrich Matthys; Victor G Lizogub; Petra Funk; Fathi A Malek
Journal:  Wien Med Wochenschr       Date:  2010-12

2.  This obscure herb works for the common cold.

Authors:  Gail Patrick; John Hickner
Journal:  J Fam Pract       Date:  2008-03       Impact factor: 0.493

Review 3.  [Pelargonium sidoides-extract (EPs 7630): registration confirms efficacy and safety].

Authors:  Andreas Conrad; Herbert Kolodziej; Volker Schulz
Journal:  Wien Med Wochenschr       Date:  2007

4.  Treatment with EPs 7630, a Pelargonium Sidoides Root Extract, Is Effective and Safe in Patients with the Common Cold: Results From a Randomized, Double Blind, Placebo-Controlled Clinical Trial.

Authors:  David S Riley; Viktor G Lizogub; Marianne Heger; Petra Funk; Heiko Mueller; Walter Lehmacher
Journal:  Integr Med (Encinitas)       Date:  2019-02

5.  Anti-inflammatory Effects of Pelargonium endlicherianum Fenzl. Extracts in Lipopolysaccharide-stimulated Macrophages.

Authors:  Ahmet Cumaoğlu; Gökçe Şeker Karatoprak; Mükerrem Betül Yerer; Müberra Koşar
Journal:  Turk J Pharm Sci       Date:  2018-04-02

Review 6.  Antimicrobial, Antiviral and Immunomodulatory Activity Studies of Pelargonium sidoides (EPs® 7630) in the Context of Health Promotion.

Authors:  Herbert Kolodziej
Journal:  Pharmaceuticals (Basel)       Date:  2011-10-10

Review 7.  Pelargonium sidoides extract EPs 7630: a review of its clinical efficacy and safety for treating acute respiratory tract infections in children.

Authors:  Domenico Careddu; Andrea Pettenazzo
Journal:  Int J Gen Med       Date:  2018-03-08

8.  Faster recovery and reduced paracetamol use - a meta-analysis of EPs 7630 in children with acute respiratory tract infections.

Authors:  Georg Seifert; Juliette Brandes-Schramm; Andrea Zimmermann; Walter Lehmacher; Wolfgang Kamin
Journal:  BMC Pediatr       Date:  2019-04-23       Impact factor: 2.125

9.  Efficacy and tolerability of EPs 7630 in patients (aged 6-18 years old) with acute bronchitis.

Authors:  W Kamin; V G Maydannik; F A Malek; M Kieser
Journal:  Acta Paediatr       Date:  2010-01-11       Impact factor: 2.299

10.  Phytomedicine in otorhinolaryngology and pulmonology: clinical trials with herbal remedies.

Authors:  Koosha Ghazi-Moghadam; Hasan Mete Inançlı; Nazanin Bazazy; Peter K Plinkert; Thomas Efferth; Serkan Sertel
Journal:  Pharmaceuticals (Basel)       Date:  2012-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.